Agenda Day 2 | December 7, 2016

8:00 – 8:30 AM Breakfast
Welcome
8:30 – 8:35 AM	Stacy L. Springs Director, BioMAN; Executive Director, CAACB, CBI, MIT view bio
Introductory Remarks
8:35 – 8:45 AM	Travis A. McCready President & Chief Executive Officer, Massachusetts Life Sciences Center view bio
Session 3: Challenges and Approaches to Manufacturing the Products of the Future
	Session Chair, Morning: Jacqueline Wolfrum, Research Scientist, CBI, MIT view bio
8:45 – 9:15 AM	Entrepreneurial Innovation at the Frontier of Health David Berry General Partner, Flagship Ventures view bio | view abstract
9:15 – 9:45 AM	The Impact of the Entry of Biosimilars: Evidence from Europe Ariel Dora Stern Assistant Professor of Business Administration, Harvard Business School view bio | view abstract
9:45 – 10:15 AM	Manufacturing Challenges for Antibody-Drug Conjugates: Past, Present and Future Nathan C. Ihle Vice President, CMC Strategy & Management, Seattle Genetics view bio | view abstract
10:15 – 10:30 AM Morning Refreshment Break
10:30 – 11:00 AM	Manufacture of Cell and Tissue Therapy Products: Cartilage Regeneration Stephen Kennedy Chief Technology Officer, Histogenics view bio | view abstract
11:00 – 11:30 AM	Paradigm Shift: Perspective of mRNA in Vaccine René Labatut Vice President, Technology Innovation, Sanofi Pasteur view bio | view abstract
11:30 AM – 12:00 PM	Targeted Genome Editing: Overview and Measurement Needs for Cell and Gene Therapies Samantha Maragh Leader, Genome Editing Program, NIST view bio | view abstract
12:00 – 12:30 PM	Global Market Access Manufacturing Considerations for Transformative Products Aura Mackenzie Senior Principal, Global Pricing and Product Strategy, Precision for Value view bio | view abstract
12:30 – 1:30 PM Lunch
	Session Chair, Afternoon: Paul W. Barone, Associate Director, BioMAN and CAACB, CBI, MIT view bio
1:30 – 2:00 PM	Engineering Red Blood Cells for Therapeutic Function Avak Kahvejian Co-founder and Chief Executive Officer, Rubius Therapeutics view bio | view abstract
2:00 – 2:30 PM	Human Microbiome Therapeutics John Aunins Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer, Seres Therapeutics view bio | view abstract
2:30 – 3:00 PM	Manufacturing Innovation via Public-Private Partnerships: Challenges and Opportunities for Emerging Therapies Krystyn J. Van Vliet Professor, Department of Materials Science and Engineering and Department of Biological Engineering; Director of Manufacturing Innovation, MIT Innovation Initiative, MIT view bio | view abstract
3:00 – 3:30 PM	AAV – Based Gene Therapy: Scalable CMC to Support Clinical Program Advancement J. Fraser Wright Co-founder and Chief Technology Officer, Spark Therapeutics view bio | view abstract
3:30 – 4:00 PM	Toward Commercialization of Exosome Technology Konstantin Konstantinov Senior Vice President, Manufacturing & Process Sciences, Codiak BioSciences view bio | view abstract
4:00 – 4:15 PM Afternoon Refreshment Break
Session 4: Panel Discussion – How do we get there from here?
4:15 – 5:00 PM	Moderator: Charles L. Cooney Professor Emeritus, Department of Chemical Engineering; Faculty Director Emeritus, Deshpande Center for Technological Innovation, MIT view bio Panelists: John Aunins Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer, Seres Therapeutics view bio Konstantin Konstantinov Senior Vice President, Manufacturing & Process Sciences, Codiak BioSciences view bio Samantha Maragh Leader, Genome Editing Program, NIST view bio J. Fraser Wright Co-founder and Chief Technology Officer, Spark Therapeutics view bio
Closing Remarks
5:00 – 5:15 PM	Stacy L. Springs Director, BioMAN; Executive Director, CAACB, CBI, MIT view bio